Literature DB >> 20399700

Impact of tumor microenvironment on oncolytic viral therapy.

Jeffrey Wojton1, Balveen Kaur.   

Abstract

Interactions between tumor cells and their microenvironment have been shown to play a very significant role in the initiation, progression, and invasiveness of cancer. These tumor-stromal interactions are capable of altering the delivery and effectiveness of therapeutics into the tumor and are also known to influence future resistance and re-growth after treatment. Here we review recent advances in the understanding of the tumor microenvironment and its response to oncolytic viral therapy. The multifaceted environmental response to viral therapy can influence viral infection, replication, and propagation within the tumor. Recent studies have unveiled the complicated temporal changes in the tumor vasculature post-oncolytic virus (OV) treatment, and their impact on tumor biology. Similarly, the secreted extracellular matrix in solid tumors can affect both infection and spread of the therapeutic virus. Together, these complex changes in the tumor microenvironment also modulate the activation of the innate antiviral host immune response, leading to quick and efficient viral clearance. In order to combat these detrimental responses, viruses have been combined with pharmacological adjuvants and "armed" with therapeutic genes in order to suppress the pernicious environmental conditions following therapy. In this review we will discuss the impact of the tumor environment on viral therapy and examine some of the recent literature investigating methods of modulating this environment to enhance oncolysis. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399700      PMCID: PMC2881175          DOI: 10.1016/j.cytogfr.2010.02.014

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  70 in total

1.  Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.

Authors:  M Zheng; S Deshpande; S Lee; N Ferrara; B T Rouse
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Diffusion parameters of the extracellular space in human gliomas.

Authors:  Lýdia Vargová; Ales Homola; Josef Zámecník; Michal Tichý; Vladimír Benes; Eva Syková
Journal:  Glia       Date:  2003-04-01       Impact factor: 7.452

3.  Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Authors:  Mark A Currier; Rebecca A Gillespie; Nancy M Sawtell; Yonatan Y Mahller; Greg Stroup; Margaret H Collins; Hirokazu Kambara; E Antonio Chiocca; Timothy P Cripe
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

4.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

5.  Reovirus activates human dendritic cells to promote innate antitumor immunity.

Authors:  Fiona Errington; Lynette Steele; Robin Prestwich; Kevin J Harrington; Hardev S Pandha; Laura Vidal; Johann de Bono; Peter Selby; Matt Coffey; Richard Vile; Alan Melcher
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

6.  Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points.

Authors:  Harald Sauthoff; Jing Hu; Cielo Maca; Michael Goldman; Sheila Heitner; Herman Yee; Teona Pipiya; William N Rom; John G Hay
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

7.  Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

Authors:  Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Joshua Shroll; Michal Nowicki; Akihiro Otsuki; E Antonio Chiocca; Balveen Kaur
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

8.  Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus.

Authors:  Sujin Lee; Mei Zheng; Bumseok Kim; Barry T Rouse
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

9.  Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.

Authors:  Akihiro Otsuki; Ankita Patel; Kazue Kasai; Masataka Suzuki; Kazuhiko Kurozumi; E Antonio Chiocca; Yoshinaga Saeki
Journal:  Mol Ther       Date:  2008-07-22       Impact factor: 11.454

10.  Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.

Authors:  Shanthi Ganesh; Melissa Gonzalez-Edick; Douglas Gibbons; Melinda Van Roey; Karin Jooss
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

View more
  39 in total

1.  Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironment.

Authors:  Jelena Vasilevska; Gustavo Antonio De Souza; Maria Stensland; Dace Skrastina; Dmitry Zhulenvovs; Raimonds Paplausks; Baiba Kurena; Tatjana Kozlovska; Anna Zajakina
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 2.  Thunder and lightning: immunotherapy and oncolytic viruses collide.

Authors:  Alan Melcher; Kelley Parato; Cliona M Rooney; John C Bell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

3.  Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.

Authors:  Gregory K Friedman; Marilyn C Haas; Virginia M Kelly; James M Markert; George Yancey Gillespie; Kevin A Cassady
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

4.  Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Authors:  Ji Young Yoo; Amy Haseley; Anna Bratasz; E Antonio Chiocca; Jianying Zhang; Kimerly Powell; Balveen Kaur
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

Review 5.  How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?

Authors:  Walter H Meisen; Balveen Kaur
Journal:  Expert Rev Neurother       Date:  2013-04       Impact factor: 4.618

Review 6.  Live viruses to treat cancer.

Authors:  Oliver Donnelly; Kevin Harrington; Alan Melcher; Hardev Pandha
Journal:  J R Soc Med       Date:  2013-07-03       Impact factor: 5.344

7.  Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Authors:  Chelsea Bolyard; Ji Young Yoo; Pin-Yi Wang; Uksha Saini; Kellie S Rath; Timothy P Cripe; Jianying Zhang; Karuppaiyah Selvendiran; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

8.  Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.

Authors:  Ilkka Liikanen; Vladia Monsurrò; Laura Ahtiainen; Mari Raki; Tanja Hakkarainen; Iulia Diaconu; Sophie Escutenaire; Otto Hemminki; João D Dias; Vincenzo Cerullo; Anna Kanerva; Sari Pesonen; Daniela Marzioni; Marco Colombatti; Akseli Hemminki
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

Review 9.  Oncolytic viruses: overcoming translational challenges.

Authors:  Jordi Martinez-Quintanilla; Ivan Seah; Melissa Chua; Khalid Shah
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

10.  Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.

Authors:  Amy Haseley Thorne; Walter H Meisen; Luke Russell; Ji Young Yoo; Chelsea M Bolyard; Justin D Lathia; Jeremy Rich; Vinay K Puduvalli; Hsiaoyin Mao; Jianhua Yu; Michael A Caligiuri; Susheela Tridandapani; Balveen Kaur
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.